共 79 条
[1]
Iriart X(2015)Risk factors of Pneumocystis pneumonia in solid organ recipients in the era of the common use of posttransplantation prophylaxis Am J Transplant 15 190-199
[2]
Challan Belval T(2011)Pneumocystis jirovecii pneumonia in kidney transplantation Transpl Infect Dis 13 551-558
[3]
Fillaux J(2016)ECIL guidelines for preventing Pneumocystis jiroveci pneumonia in patients with haematological malignancies and stem cell transplant recipients J Antimicrob Chemother 71 2397-2404
[4]
Esposito L(2004)Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients Clin Microbiol Rev 17 770-782
[5]
Lavergne RA(2009)Evolving health effects of Pneumocystis. One hundred years of progress in diagnosis and treatment JAMA 301 2578-2585
[6]
Cardeau-Desangles I(1984)Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies Ann Intern Med 100 663-671
[7]
Goto N(2011)Considerations when prescribing trimethoprim-sulfamethoxazole CMAJ 183 1851-1858
[8]
Oka S(2007)Prophylaxis of Pnumocystis pneumonia in immunocompromised non-HIV infected patients: systematic review and meta-analysis of randomized controlled trials Mayo Clin Proc 82 1052-1059
[9]
Maertens J(1999)Terry Beirn community programs for clinical research on AIDS (CPCRA). A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocuystis cariniii pneumonia in human immunodeficiency virus-infected persons Clin Infect Dis 29 775-783
[10]
Cesaro S(1999)Editorial response: prophylaxis for Pneumocystis carinii pneumonia--an evolving tale of two populations Clin Infect Dis 29 784-786